Organogenesis, Inc.

Summary

Financial Advisor

Organogenesis™ is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets.

Carl Marks Advisors (CMA) acted as the exclusive financial advisor to Organogenesis, Inc. during its Chapter 11 bankruptcy, leading creditor and supplier negotiations, conducting valuations, and assisting in the development of a reorganization plan. CMA’s valuation of the company and its intellectual property was pivotal in projecting future cash flows and guiding the successful restructuring.

The firm also helped negotiate third-party sales and marketing agreements, enabling Organogenesis to transition from its relationship with Novartis and reemerge as an independent company. CMA testified in support of the plan and secured a consensual settlement with creditors, facilitating a smooth exit from bankruptcy.

Engagement Highlights

CMA provided a valuation of the company and its IP as the basis for the proposed plan of reorganization, which facilitated the company’s successful exit from bankruptcy.
Assisted the company in negotiating sales and marketing agreements with numerous third parties, as the company ceased its relationship with Novartis and emerged as an independent company.
In performing a valuation of the company and structuring the Plan of Reorganization, the value of Organogenesis’ intellectual property was critical. This IP formed the basis of projecting future cash flow streams that the company should be able to access.
Testified in connection with the Plan of Reorganization and, ultimately, structured a consensual settlement with the creditors committee.

Organogenesis, Inc.

Summary

Financial Advisor

Engagement Highlights

Sign Up for Our Newsletter